Corcept Therapeutics (CORT) CSO exercises 150,000 options, withholds shares for taxes

Rhea-AI Filing Summary

Corcept Therapeutics Chief Scientific Officer Hazel Hunt reported an option exercise and related share withholding. On February 9, 2026, Hunt exercised stock options for 150,000 shares of common stock at an exercise price of $3.88 per share, converting a stock option that was fully exercisable and scheduled to expire on February 26, 2026.

To cover the option exercise price and associated tax withholding in a net (cashless) transaction, 77,968 common shares were withheld at a price of $41.31 per share. After these transactions, Hunt directly held 255,437 shares of Corcept Therapeutics common stock.

Insider Trade Summary

150,000 shares exercised/converted

Mixed 3 txns

Insider Hunt Hazel

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	150,000	$0.00	--
Exercise	Common Stock	150,000	$3.88	$582K
Tax Withholding	Common Stock	77,968	$41.31	$3.22M

Holdings After Transaction: Stock Option (right to buy) — 0 shares (Direct); Common Stock — 333,405 shares (Direct)

Footnotes (1)

1. These shares were withheld so the Reporting Person could satisfy the exercise price and the withholding of taxes arising from a net (cashless) exercise of stock options. The options subject to the net exercise were to expire on February 26, 2026. Fully exercisable.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hunt Hazel

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/09/2026		M		150,000	A	$3.88	333,405	D
Common Stock	02/09/2026		F(1)		77,968	D	$41.31	255,437	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$3.88	02/09/2026		M			150,000	(2)	02/26/2026	Common Stock	150,000	$0.00	0	D

Explanation of Responses:

1. These shares were withheld so the Reporting Person could satisfy the exercise price and the withholding of taxes arising from a net (cashless) exercise of stock options. The options subject to the net exercise were to expire on February 26, 2026.

2. Fully exercisable.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for Hazel Hunt	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Hazel Hunt report for Corcept Therapeutics (CORT)?

Hazel Hunt reported exercising stock options for 150,000 Corcept Therapeutics shares on February 9, 2026. The transaction converted a fully exercisable option and increased her direct common stock holdings, subject to shares withheld for taxes and exercise costs in a net, or cashless, transaction.

How many Corcept Therapeutics shares did Hazel Hunt acquire and at what exercise price?

Hazel Hunt exercised options covering 150,000 Corcept Therapeutics common shares at an exercise price of $3.88 per share. This derivative exercise converted stock options into common stock, replacing the option position with directly held shares before accounting for tax-related share withholding.

Why were 77,968 Corcept Therapeutics shares withheld in Hazel Hunt’s Form 4 filing?

The 77,968 shares were withheld to satisfy the option exercise price and related tax withholding obligations. The filing specifies this occurred through a net, or cashless, exercise of stock options, meaning part of the exercised shares covered costs instead of being retained as additional holdings.

What is Hazel Hunt’s Corcept Therapeutics share ownership after the reported transactions?

Following the February 9, 2026 transactions, Hazel Hunt directly owned 255,437 shares of Corcept Therapeutics common stock. This figure reflects the 150,000 shares received from the option exercise, less the 77,968 shares withheld to cover the exercise price and tax obligations.

When were Hazel Hunt’s exercised Corcept stock options scheduled to expire?

The stock options exercised by Hazel Hunt were scheduled to expire on February 26, 2026. The Form 4 notes that these options were fully exercisable, and the exercise on February 9, 2026 occurred shortly before the stated expiration date of the derivative award.

What role does Hazel Hunt hold at Corcept Therapeutics (CORT)?

Hazel Hunt serves as Chief Scientific Officer at Corcept Therapeutics. The Form 4 identifies her as an officer, not a director or 10% owner, and reports her direct ownership of common stock following the option exercise and related tax-withholding share disposition.